PAREXEL International Co. (NASDAQ:PRXL) updated its FY16 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $3.40-3.58 for the period, compared to the Thomson Reuters consensus estimate of $3.30, Market Beat Ratings reports. The company issued revenue guidance of $2.085-2.115 billion, compared to the consensus revenue estimate of $2.14 billion.PAREXEL International also updated its Q3 guidance to $0.84-0.92 EPS.

A number of research analysts have recently commented on the stock. Avondale Partners cut shares of PAREXEL International from a market perform rating to an underperform rating and dropped their target price for the stock from $60.00 to $49.00 in a report on Monday. Evercore ISI raised shares of PAREXEL International from a hold rating to a buy rating and set a $77.50 target price for the company in a report on Wednesday, January 6th. Citigroup Inc. reissued a buy rating and issued a $71.00 target price (up previously from $64.00) on shares of PAREXEL International in a report on Thursday, December 3rd. Deutsche Bank reissued a hold rating and issued a $68.00 target price on shares of PAREXEL International in a report on Sunday, November 1st. Finally, Jefferies Group increased their target price on shares of PAREXEL International from $66.00 to $68.00 in a report on Friday, October 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $70.06.

PAREXEL International Co. (NASDAQ:PRXL) traded down 1.65% during mid-day trading on Wednesday, reaching $62.50. 818,385 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $65.97 and a 200-day moving average of $66.21. PAREXEL International Co. has a one year low of $57.01 and a one year high of $76.17. The stock has a market cap of $3.33 billion and a price-to-earnings ratio of 25.72.

PAREXEL International (NASDAQ:PRXL) last announced its quarterly earnings results on Wednesday, January 27th. The company reported $0.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.18. The company had revenue of $518.50 million for the quarter, compared to the consensus estimate of $523.03 million. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.69 earnings per share. On average, equities research analysts anticipate that PAREXEL International Co. will post $3.28 earnings per share for the current year.

In related news, Director Eduard E. Holdener sold 2,200 shares of the company’s stock in a transaction that occurred on Tuesday, November 24th. The shares were sold at an average price of $67.66, for a total value of $148,852.00. Following the transaction, the director now directly owns 13,171 shares in the company, valued at $891,149.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Richard L. Love sold 1,330 shares of the company’s stock in a transaction that occurred on Tuesday, December 1st. The stock was sold at an average price of $68.21, for a total transaction of $90,719.30. Following the completion of the transaction, the director now owns 85,440 shares in the company, valued at $5,827,862.40. The disclosure for this sale can be found here.

PAREXEL International Corporation (NASDAQ:PRXL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.

12 Month Chart for NASDAQ:PRXL

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.